Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.39 |
| ▸ | PIK3R2 | O00459 | 2/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19989834 | 0.89 | PIK3R2 (0.33) | PIK3R2CSF1RMEN1MAPTKMT2A | |
| SCHEMBL19989780 | 0.88 | SMN1; SMN2 (0.38) | NR1H2NR1H3PIK3R2MEN1KMT2A | |
| SCHEMBL19989944 | 0.80 | AURKB (0.35) | PIK3R2CSF1RMEN1MAPTKMT2A | |
| SCHEMBL19989837 | 0.79 | PIK3R2 (0.48) | NR1H2NR1H3PIK3R2CSF1RMEN1 | |
| SCHEMBL19989800 | 0.79 | PIK3R2 (0.36) | PIK3R2MEN1MAPTKMT2A | |
| SCHEMBL19990052 | 0.77 | TGFBR1 (0.34) | PIK3R2MEN1MAPTKMT2A | |
| SCHEMBL19988976 | 0.76 | MAPT (0.45) | NR1H2NR1H3PIK3R2MAPT | |
| SCHEMBL19990111 | 0.75 | TGFBR1 (0.34) | PIK3R2MEN1CYP3A4MAPTKMT2A | |
| SCHEMBL19989898 | 0.75 | PIK3R2 (0.57) | NR1H2NR1H3PIK3R2 | |
| SCHEMBL19989842 | 0.75 | PIK3R2 (0.37) | PIK3R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227350-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180086768-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227350-B2 | Phosphatidylinositol 3-kinase inhibitors | PIK3CA, AKT3, AKT1 | NR1H2 3069/4885NR1H3 2669/4885PIK3R2 13/4885 |
| US-20180086768-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, AKT3, AKT1 | NR1H2 3069/4885NR1H3 2669/4885PIK3R2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.